MMS’ Post

Continued Emphasis on the Brain Disease Model: Despite its limitations, the brain disease model continues to dominate largely because it supports the development and funding of medical treatments and pharmaceutical interventions, which are concrete, scalable, and economically beneficial for the medical and pharmaceutical industries. Additionally, this model has played a significant role in shaping public policies and research agendas. #Addiction #Recovery

Very interesting working paper on fair price setting in the pharmaceutical industry taking into accounts return to early investor, the state, and health value https://lnkd.in/deSAsviu

Scorpion venom is one of nature's treasures with a plethora of therapeutic effects that find extensive utility in the pharmaceutical industry. Among its notable effects are its anti-inflammatory, anticancer, and neurological disease-treating properties. Recent research has shown that compounds found in scorpion venom can ameliorate chronic conditions such as arthritis and cardiovascular diseases. Given the therapeutic potential of these compounds, the pharmaceutical industry is keen on harnessing them for the development of novel and efficacious drugs. #ScorpionVenom #Pharmaceuticals #MedicalResearch #DrugDevelopment #TherapeuticCompounds #HealthcareInnovation

India continues to strengthen its position as a global pharmaceutical leader. During the iPHEX 2024 event, the director general of Pharmexcil, K Raja Bhanu, highlighted the remarkable growth in Indian pharmaceutical exports, which surpassed $27.9 billion in FY24, a 90% rise from FY14. This reinforces India’s vital role in supplying generic medicines globally, contributing significantly to healthcare systems, particularly in the U.S. where Indian generics have saved over $200 billion. India’s pharma industry is also making strides in innovation, exemplified by the development of NexCAR19, the country’s first indigenous CAR-T cell therapy. On the international front, Merck made a key announcement on 2nd September 2024 regarding its Phase III clinical trial for cladribine capsules (MyClad) in treating generalized Myasthenia Gravis (gMG). This study aims to explore the efficacy and safety of the oral treatment, potentially offering a new option for managing this autoimmune disease, which affects the neuromuscular junction. #pharmatreds #indianpharmaindustry #PharmaTalk #PharmaEducation #PharmaIndustry #HealthcareInnovation #PharmaCareers #ClinicalResearch #PharmaUpskilling #PharmaTraining #PharmaStudents #STEMEducation #PharmaSkills #PharmaOpportunities #RegulatoryAffairs #MedicalWriting #PharmaLeadership #PharmaGrowth #PharmaCommunity #PharmaFuture

🌐 PTC Therapeutics has officially filed a patent for a groundbreaking pharmaceutical composition targeting various diseases like a-synucleinopathy, liver diseases, and more. 🧪 The composition boasts a unique blend of oil, propylene glycol laurates, polysorbate 80, and Compound 1. 💡 Did you know? According to GlobalData’s comprehensive company profile on PTC Therapeutics, the Human telomerase RT biomarker emerged as a key innovation area identified from their patents. 📈 As of January 2024, PTC Therapeutics holds a remarkable grant share of 36%, reflecting their commitment to advancing pharmaceutical solutions. Grant share is determined by the ratio of granted patents to the total number of patents. Read more: https://lnkd.in/gcWhJgSU Kudos to PTC Therapeutics for pushing the boundaries of medical research and contributing to the future of healthcare! 🌟 #pharmaceuticaltechnology #globaldata #PharmaInnovation #MedicalResearch #PTCTherapeutics #PatentFiling #HealthcareAdvancements 🌐👩🔬🔬

I had a great time presenting at GeneOnline's STLI Webinar to an insightful audience of APAC executives and regulators, alongside Dr Jailal Ablack from Entos Pharma. Thank you to Taiwan's Science and Technology Law Institute (STLI) for the invitation! Key takeaways: 💎 mRNA is becoming the fourth pillar of biopharmaceutical innovation, alongside small molecules, biologics, and cell & gene therapies. The number of mRNA therapies in R&D has skyrocketed, highlighting its vast potential. 🗺 Navigating the regulatory landscape is still challenging, but early engagement with FDA and EMA can significantly boost R&D efficiency. Exciting developments like the FDA's Platform Technology Designation and updated gene therapy guidelines are paving the way for faster approvals and reduced costs. Read more below. #Biopharma #mRNA #Innovation #RegulatoryAffairs #STLIWebinar #Healthcare

I am thrilled to announce the publication of our chapter titled "Pyridostigmine: An Acetylcholinesterase as First-Line Therapy Drug for Myasthenia Gravis" in the latest volume of Drug Details: Skeletomuscular, Integumentary & Endocrine System. This work evaluates the efficacy, side effects, and patient experiences of pyridostigmine, the most commonly used drug for treating myasthenia gravis. - Prof. Shital Kalekar - Harshita Rajeev Agarwal - Ronit Handa - Manas Joshi Our research highlights important findings on the use of pyridostigmine, including its historical context, physicochemical properties, and pharmacokinetics. We hope this contributes valuable insights to the medical and pharmaceutical communities. #medicalresearch #pharmacology #myastheniagravis #pyridostigmine #drugefficacy #healthcareinnovation #pharmacognosy

Excited to share my recent publication in the International Journal of Pharmaceutical Sciences Review and Research titled "Alternative Approaches to Neuropathic Pain: A Review of Non-Analgesic Therapies," published on December 15, 2023. In this comprehensive review, I delved into innovative strategies and non-analgesic therapies for managing neuropathic pain. Drawing upon extensive research and literature, the paper explores emerging perspectives that extend beyond conventional analgesic treatments. It highlights the potential of diverse interventions, providing valuable insights for healthcare professionals, researchers, and practitioners in the field. Grateful for the collaborative efforts that contributed to this work, I look forward to continued discussions and advancements in the realm of neuropathic pain management. The full article is available for reference on the journal's platform. DOI URL: https://lnkd.in/geSASkAq https://lnkd.in/gy7WCFjU #NeuropathicPain #MedicalResearch #NonAnalgesicTherapies #PharmaceuticalSciences #PainManagement #pharmacology

We invite you to explore a recent publication in the Journal of Pharmacy & Pharmaceutical Sciences (JPPS), titled "Revolutionizing Pharmacokinetics: The Dawn of AI-Powered Analysis." This pioneering article delves into the integration of artificial intelligence with pharmacokinetic analysis, representing a significant advancement in drug development and personalized medicine. The publication provides in-depth insights and introduces innovative methodologies that highlight the transformative potential of generative AI within the pharmaceutical sciences. We encourage professionals in the field to read this article for a deeper understanding of the evolving landscape in pharmacokinetics research. Access the full text of the article here: https://lnkd.in/eGWsaVHj

What is crucial for pharmaceutical companies to succeed with their clinical trials? Selected collection sites need to be audited in accordance to legal requierements.  Anke Löffler is responsible for the qualification of apheresis units for autologous lymphocyte collections to ensure compliance with GMP regulations.   She has already audited and supported more than 100 clinics and collection centers worldwide. Do you need support regarding the regulatory requirements that must be followed when dealing with human starting material? Get in touch with our Cellex experts. Your contact: businessdevelopment@cellex.me #startingmaterial #leukopaks #mobilizedleukopaks #wholeblood #bonemarrow #msc #celltherapy #genetherapy #research #healthydonormaterial #manufacturing #science #cdmo #ipsc